Suppr超能文献

抗磷脂综合征伴严重血小板减少症患者广泛性深静脉血栓形成的治疗挑战——一项为期2年的随访研究

Challenges in Treating Extensive Deep Vein Thrombosis with Severe Thrombocytopenia in Patients with Antiphospholipid Syndrome-A Follow-up of 2 Years.

作者信息

Wei Lee Kai, Sule Ashish Anil

机构信息

Student Assistantship Programme, Lee Kong Chian School of Medicine, Singapore.

Department of General Medicine, Subspecialty of Vascular Medicine and Hypertension, Tan Tock Seng Hospital, Singapore.

出版信息

Int J Angiol. 2019 Jul 30;33(1):66-69. doi: 10.1055/s-0039-1693996. eCollection 2024 Feb.

Abstract

Thrombocytopenia is one of the most common manifestations of antiphospholipid syndrome (APS). There is little evidence or definitive guidelines regarding the treatment of APS with thrombocytopenia. We describe a patient with APS and moderate-to-severe thrombocytopenia and the challenges of balancing anticoagulation with thrombocytopenia. A 19-year-old male patient presented with right lower limb swelling to the emergency department with a history of gradually worsening right leg swelling for 1 week and was diagnosed with right leg proximal deep vein thrombosis. Ultrasound Doppler of the right lower limb revealed complete venous thrombosis from the level of the popliteal vein to the distal superficial femoral vein. Subsequently, he was found to have triple-positive APS and moderate-to-severe immune thrombocytopenia, with a platelet count nadir of 31 × 10 to the ninth power/L. He was started on anticoagulation with warfarin. The severe thrombocytopenia was not treated with immunosuppressants and the platelets fluctuated in the range of moderate-to-severe thrombocytopenia but did not develop any rethrombotic or bleeding events. His platelets varied from 31 × 10 to the ninth power/L to 106 × 10 to the ninth power/L. This case report demonstrates that it may be safe to hold off treatment for thrombocytopenia in APS, even in cases of severe thrombocytopenia. Treatment with immunosuppressants may be instituted only when platelet levels fall below 20 × 10 to the ninth power/L or when there is clinically significant bleeding, as in primary immune thrombocytopenia.

摘要

血小板减少是抗磷脂综合征(APS)最常见的表现之一。关于APS合并血小板减少的治疗,几乎没有证据或明确的指南。我们描述了一名患有APS和中度至重度血小板减少的患者,以及在抗凝与血小板减少之间进行平衡时所面临的挑战。一名19岁男性患者因右下肢肿胀就诊于急诊科,其右腿肿胀逐渐加重已有1周病史,被诊断为右下肢近端深静脉血栓形成。右下肢超声多普勒检查显示,从腘静脉水平至股浅静脉远端存在完全性静脉血栓形成。随后,发现他患有三联阳性APS和中度至重度免疫性血小板减少,血小板计数最低点为31×10⁹/L。开始使用华法林进行抗凝治疗。严重血小板减少未用免疫抑制剂治疗,血小板在中度至重度血小板减少范围内波动,但未发生任何再血栓形成或出血事件。他的血小板计数在31×10⁹/L至106×10⁹/L之间变化。本病例报告表明,对于APS合并血小板减少,即使是严重血小板减少的情况,推迟治疗血小板减少可能是安全的。仅当血小板水平低于20×10⁹/L或出现临床上显著的出血时,才可能如原发性免疫性血小板减少症那样使用免疫抑制剂进行治疗。

相似文献

5
Thrombocytopenia in high-risk patients with antiphospholipid syndrome.抗磷脂综合征高危患者的血小板减少症。
J Thromb Haemost. 2018 Mar;16(3):529-532. doi: 10.1111/jth.13947. Epub 2018 Jan 25.

本文引用的文献

4
Thrombocytopenia in high-risk patients with antiphospholipid syndrome.抗磷脂综合征高危患者的血小板减少症。
J Thromb Haemost. 2018 Mar;16(3):529-532. doi: 10.1111/jth.13947. Epub 2018 Jan 25.
7
Treatment of catastrophic antiphospholipid syndrome.灾难性抗磷脂综合征的治疗
Curr Opin Rheumatol. 2016 May;28(3):218-27. doi: 10.1097/BOR.0000000000000269.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验